Eye protection product containing deguelin and application

Abstract

The invention provides an eye protection product containing deguelin and application, and belongs to the technical field of eye health. The invention provides the application of the deguelin in preparation of the eye protection product, it is found that the deguelin has the protection effect on eye cell apoptosis, retina light damage and the like in a cell model and a mouse model, and it is proved that the deguelin has the remarkable anti-light-damage eye protection effect. The invention proposes that the deguelin has a protective effect on the retina light injury for the first time, and can be developed and applied to the medicines for treating the retina light injury disease and functional products for relieving visual fatigue and the like.

Description

Technical Field

[0001] The invention belongs to the technical field of eye health, and specifically relates to an eye protection product containing deguelin and application thereof. Background Art

[0002] Eye health is an important part of national health, involving people of all ages throughout their lives. However, as electronic products gradually penetrate people's lives, excessive use of eyes has become the norm, troubling people from children to the elderly. Myopia problems in children and adolescents, high blue light exposure problems in young and middle-aged people, and macular degeneration problems in the elderly are all related to varying degrees of retinal light damage. In particular, age-related macular degeneration (AMD) is a difficult-to-treat disease that seriously damages vision and is one of the leading causes of blindness in adults over 50 years old worldwide. With the aging of the population, the incidence of AMD is also increasing year by year. It is estimated that the number of AMD patients worldwide will reach 288 million by 2040, and there is currently no clinically effective drug treatment except for anti-VEGF drugs. It can be seen that related retinal diseases and even visual impairment caused by retinal light damage have a very serious impact on the physical and mental health and quality of life of the people, and increase the burden on families and society. Therefore, preventing retinal light damage and promoting visual health have become important issues that need to be urgently addressed in the Healthy China strategy. Summary of the invention

[0003] The present invention provides an eye protection product containing deguelin and application thereof, and explores the significant eye protection effect of deguelin in resisting light damage.

[0004] The invention provides application of deguelin in preparing eye protection products.

[0005] Preferably, the eye protection product includes at least one of the following functions: (1) treating and / or preventing eye diseases associated with retinal light damage;

[0006] (2) Treat and / or alleviate ocular symptoms associated with retinal photodamage;

[0007] (3) Relieve visual fatigue.

[0008] Preferably, the eye protection product has at least one of the following functions: (a) protecting Müller cells from damage by strong light;

[0009] (b) Improve retinal cell damage caused by light exposure;

[0010] (c) Improve retinal cell apoptosis caused by light exposure;

[0011] (d) Protective effect against light-induced oxidative stress damage;

[0012] (e) Improve the cellular inflammatory response caused by light;

[0013] (f) Relieve visual fatigue.

[0014] Preferably, the types of the eye protection products include foods, drugs and / or medical device products.

[0015] The present invention provides an application of deguelin in the preparation of a drug related to the prevention and / or treatment of retinal light damage diseases.

[0016] The present invention also provides a drug related to the prevention and / or treatment of retinal light damage diseases, comprising deguelin and a pharmaceutically acceptable excipient.

[0017] Preferably, the working concentration of deguelin is not less than 30 μM.

[0018] The present invention also provides an application of deguelin in the preparation of a functional food for relieving visual fatigue.

[0019] The present invention also provides a functional food for relieving visual fatigue, taking deguelin as an active ingredient and further comprising a food-acceptable excipient.

[0020] Preferably, the dosage form of the functional food includes at least one of the following: ointment, powder, liquid, tablet, gel, capsule and granule.

[0021] Beneficial effects: In both the human primary retinal Müller cell light damage model and the mouse retinal light damage model, the present invention finds that deguelin has a protective effect on ocular cell apoptosis, retinal light damage, etc., and confirms that deguelin has a significant eye protection effect against light damage. Specifically, the deguelin of the present invention has the functions of treating and / or preventing eye diseases or symptoms related to retinal light damage and relieving visual fatigue, which are reflected in: protecting Müller cells from strong light damage, improving the cell damage of the retina caused by light, improving the apoptosis of retinal cells caused by light, having a protective effect on the oxidative stress damage caused by light, improving the cell inflammatory response caused by light, and relieving visual fatigue. In summary, the present invention first proposes that deguelin has a protective effect on retinal light damage and can be developed and applied in drugs for treating retinal light damage diseases and functional products for relieving visual fatigue. Description of the Drawings

[0022] Figure 1 It is a graph of the cell viability results of human primary Müller cells in the control group and the 30 μM deguelin pre-protection group under weak light and strong light irradiation conditions;

[0023] Figure 2It is a H&E staining diagram of mouse retina; in the figure, A represents the H&E staining diagram of mouse retina tissue and the thickness diagrams of outer nuclear layer and inner nuclear layer of retina, scale bar: 20μm; B and C represent the quantitative diagrams of the thickness of outer nuclear layer and inner nuclear layer of retina, number of mice (n = 5 - 6).

[0024] Figure 3 It is a TUNEL staining diagram of mouse retina cells; in the figure, A represents the TUNEL fluorescence staining diagram of mouse retina, DAPI blue fluorescence represents cell nuclei, and TUNEL red fluorescence represents apoptotic cells, scale bar: 500μm and 100μm; B represents the quantitative diagram of the fluorescence intensity of apoptotic cells in retina, number of mice (n = 5 - 6).

[0025] Figure 4 It is a diagram of the content of malondialdehyde in mouse plasma, number of mice (n = 5).

[0026] Figure 5 It is a diagram of the content of IL-6 in mouse plasma, number of mice (n = 6 - 7). Detailed implementation manners

[0027] The present invention provides the application of deguelin in the preparation of eye care products.

[0028] The deguelin in the present invention is a small molecule monomer compound, molecular formula: C 23 H 22 O6, molecular weight: 394.42, its CAS: 522 - 17 - 8. The present invention does not have special limitations on the source of the deguelin, and it can be purchased or prepared by oneself. In the examples, the deguelin with the product number T6817 purchased from TargetMol is taken as an example for illustration, but it cannot be regarded as the entire protection scope of the present invention only.

[0029] The eye care products in the present invention preferably include at least one of the following functions: (1) treating and / or preventing eye diseases related to retinal light injury; (2) treating and / or relieving eye symptoms related to retinal light injury; (3) relieving visual fatigue; more preferably include at least one of the following effects: (a) protecting Müller cells from strong light injury; (b) improving cell damage in the retina caused by light; (c) improving apoptosis of retinal cells caused by light; (d) having a protective effect on oxidative stress injury caused by light; (e) improving cell inflammatory response caused by light; (f) relieving visual fatigue.

[0030] The preferred types of the eye care products in the present invention include foods, drugs and / or medical device products, and among them, foods preferably include ordinary foods or functional foods such as health foods.

[0031] The present invention provides the use of deguelin in the preparation of a drug related to the prevention and / or treatment of retinal light damage diseases.

[0032] In the embodiments of the present invention, a human primary retinal Müller cell light damage model and a mouse retinal light damage model were constructed. After treatment with deguelin, it was found that deguelin has a protective effect on ocular cell apoptosis, retinal light damage, etc., and can be applied to the development and application of drugs for treating retinal light damage diseases and functional products such as relieving visual fatigue.

[0033] The present invention also provides a drug related to the prevention and / or treatment of retinal light damage diseases, comprising deguelin and a pharmaceutically acceptable excipient.

[0034] In the embodiments of the present invention, a human primary Müller cell photo-stress model derived from peripheral retinal tissue was treated with 30 μM deguelin. The results showed that compared with low-light irradiation, after 4 h of high-light irradiation, the viability of human primary Müller cells in the control group decreased significantly. After pre-incubating with 30 μM deguelin for 24 h, although the cell viability was slightly lower than that under low-light irradiation, it was still significantly higher than that in the control group under high-light irradiation, indicating that deguelin can significantly protect Müller cells from high-light damage after administration.

[0035] In the embodiments of the present invention, a mouse light damage model was also treated with dosages of 2 mg / kg (low dose) and 4 mg / kg (high dose) of deguelin. Both low-dose and high-dose deguelin administration could well improve the morphological changes in the inner / outer nuclear layers of the retina caused by light irradiation, and increase the thickness of the outer nuclear layer and the inner nuclear layer, indicating that deguelin can better improve the cell damage in the retina caused by light irradiation; high-dose deguelin could significantly improve the apoptosis of retinal cells caused by light irradiation, indicating that deguelin has an improving effect on retinal cell apoptosis caused by light irradiation; light irradiation caused an increase in the plasma MDA level in the model group mice, while high-dose deguelin could significantly reduce the MDA level, indicating that deguelin can reduce the level of membrane lipid peroxidation and has a protective effect on oxidative stress damage caused by light irradiation; light irradiation could cause an increase in the plasma IL-6 level in the model group mice, indicating that light irradiation led to an increase in the IL-6-mediated inflammatory response in the body, while both low-dose and high-dose deguelin could significantly reduce the IL-6 level in the body, indicating that deguelin has an improving effect on the cell inflammatory response caused by light irradiation.

[0036] The present invention also provides the use of deguelin in the preparation of a functional food for relieving visual fatigue.

[0037] The dosage form of the functional food of the present invention preferably includes at least one of the following: ointment, powder, liquid, tablet, gel, capsule, and granule.

[0038] The present invention also provides a functional food for relieving visual fatigue, which uses deguelin as the active ingredient and also includes food-acceptable excipients.

[0039] To further illustrate the present invention, the following describes in detail an eye protection product containing deguelin and its application provided by the present invention in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0040] The drugs and preparation methods used in the embodiments of the present invention are as follows:

[0041] Deguelin was purchased from TargetMol, product number: T6817. When used in cell experiments, it was prepared with DMSO as the solvent, and the final concentration was 30 μM; when used in mouse experiments, deguelin was prepared into a suspension with sodium carboxymethylcellulose (CMC-Na) solvent and administered to mice by gavage, with a low dose of 2 mg / kg and a high dose of 4 mg / kg.

[0042] Positive drug: lutein, yellow powder, batch number A1600, purchased from Chengdu Mansite Biotechnology Co., Ltd. The usage method was to prepare it into a suspension with CMC-Na and administer it to mice by gavage, with a dosage of 100 mg / kg.

[0043] Example 1

[0044] 1. Experimental method:

[0045] 1.1 Culture and passage of primary human retinal Müller cells

[0046] Primary human retinal Müller cells were obtained from the donor retinal tissue for culture.

[0047] Obtaining of primary human Müller cells: The retina was separated from the retinal pigment epithelium-choroid-sclera eye cup using surgical scissors and forceps. A 1 cm 2Place the retinal tissue of different sizes in a T25 culture bottle containing 5mL complete DMEM culture medium. Wrap the culture bottle with tin foil and then place it in a 4℃ environment overnight. Preheat the trypsin digestion solution in a 37℃ water bath. Transfer the retinal tissue to a new culture bottle containing 5mL pre-heated trypsin digestion solution and place it in a 37℃, CO2 incubator for 60min. Use sterile tweezers to transfer the digested retina to a cell culture dish containing 5mL complete DMEM culture medium and cut it into small pieces (1×1mm) under a dissecting microscope. Transfer these small pieces of retinal tissue together with the complete DMEM culture medium back to the T25 culture bottle. Use an 18G needle with a 90-degree top bend to evenly distribute these small retinal tissues at the bottom of the culture bottle and press them to the bottom of the culture bottle under a microscope. Then, carefully add 2mL complete DMEM culture medium. Place the culture flask vertically in a cell culture incubator (37°C, CO2) for 15 minutes to allow the retinal fragments to better adhere to the bottom of the T25 culture flask, then place the T25 culture flask horizontally and culture it in the incubator. When cultured to the 7th day, add 2 mL of complete DMEM culture medium. Minimize the disturbance of the culture flask during the whole process.

[0048] Culture of primary human Müller cells: On the 10th day of culture, replace with 4 mL of complete DMEM culture medium, and then maintain the frequency of changing the medium twice a week. It takes about 2 to 3 weeks for primary human Müller cell colonies to emerge from the tissue, and then another 2 to 3 weeks to reach 80 to 90% density.

[0049] Passaging of primary human Müller cells: The digestion time of primary human Müller cells is longer than that of general cell lines. The initial passaging is 1:1, and after P2, 1:2-1:3 passaging can be adopted. Usually P3 can be used for cell experiments. Although it can be passed to P10 under normal circumstances, it also depends on the conditions of different donors. The specific passaging steps are: remove the culture medium and rinse with 3mL sterile PBS solution. Remove the PBS solution and add 2ml of trypsin digestion solution to each T25 culture flask for digestion (37℃, 6-8min). When more than half of the cells are detached from the bottom of the culture flask, add 2mL of complete DMEM culture medium to stop digestion. Use a pipette to separate all cells and transfer all liquids to a 15mL centrifuge tube. Separate primary human Müller cells by centrifugation (200g, 5min, 20℃). Resuspend the cell pellet with 1mL of complete DMEM culture medium and transfer it to a new T25 culture flask containing 3mL of complete DMEM culture medium and return it to the incubator for culture.

[0050] Cryopreservation and resuscitation of human primary Müller cells: Digest and collect human primary Müller cells as described above. Resuspend the cell pellet with 1 mL of cryopreservation solution and transfer it to a cryotube. Transfer the cryotube-containing cell program cooling box to an -80°C refrigerator for cryopreservation. Transfer the cryotube to a liquid nitrogen tank for storage the next day. When resuscitating the cells, thaw the cryotube in a pre-warmed 37°C water bath. After it completely melts, add the suspension to 4 mL of pre-prepared complete DMEM culture medium, mix well, and centrifuge at 200 g for 5 min at room temperature. Then discard the supernatant, resuspend the cells with 4 mL of complete DMEM culture medium, transfer them to a cell culture flask, and place them in a 37°C, 5% CO2 incubator for culture.

[0051] 1.2 Photostress modeling of human retinal primary Müller cells and treatment with deguelin

[0052] Seed the human primary Müller cells in the logarithmic growth phase at 5,000 cells / well in a 96-well plate and culture them in a 37°C, 5% CO2 incubator for 24 h. Aspirate the culture medium. Set up 6 replicate wells in the deguelin drug solution group and add 100 μL of deguelin drug solution diluted with DMEM solution in advance to each well, with a concentration of 30 μM. The control group was added 100 μL of DMEM solution. Use a self-made high-intensity light irradiation system in the laboratory to perform photostress modeling on human retinal primary Müller cells cultured in vitro. The high-intensity light irradiation group was irradiated with high-intensity light of 32 k Lux for 4 h, and the low-intensity light irradiation group was irradiated with low-intensity light of 5 k Lux for 4 h. Then use the AlamarBlue kit to detect cell viability.

[0053] 1.3 Detection of cell viability

[0054] After the cells are stimulated by light, use the AlamarBlue kit to detect cell viability. The specific steps are as follows: Discard the cell culture supernatant, wash twice with 100 μL of PBS, add 100 μL of AlamarBlue reagent diluted 1:10 with DMEM solution, and incubate in a 37°C, 5% CO2 incubator for 4 h. Use a microplate reader to read the fluorescence of each well at an excitation wavelength of 544 nm and an emission wavelength of 590 nm.

[0055] 2. Experimental results:

[0056] The above method was used to construct a light stress model of human primary Müller cells derived from peripheral retinal tissue, and the effect of 30 μM deguelin on the viability of Müller cells after strong light irradiation was explored. The results of statistical analysis were expressed as mean ± SE. Statistical analysis was performed using GraphPad Prism (Version 9.3.1) software, and paired t-tests were used to compare the statistical differences between groups. *P<0.05, ****P<0.0001; P<0.001. * indicates the statistical difference under different light intensities in the same group, and ns represents no statistical difference. # indicates the statistical difference between the deguelin administration group and the control group under strong light irradiation conditions. The results are as Figure 1 shown. Compared with weak light irradiation, the viability of human primary Müller cells in the control group decreased significantly after 4 h of strong light irradiation. After pre-incubating with 30 μM deguelin for 24 h, although the cell viability was slightly lower than that under weak light irradiation, it was still significantly up-regulated compared with the control group under strong light irradiation, enabling deguelin administration to significantly protect Müller cells from strong light damage.

[0057] Example 2

[0058] In Example 2, Prism 8 software was used for statistical chart drawing and statistical analysis. All data were expressed as mean ± standard error. Independent sample t-tests were used to analyze the differences between two groups, and P<0.05 indicated that the differences were statistically significant.

[0059] 1. Experimental methods and results

[0060] 1.1 Experimental animals

[0061] 8-week-old male BALB / c mice were purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd. Before the start of the experiment, all mice were adaptively fed with 12:12 h light / dark in an animal house at a certain temperature and humidity for 1 week, and normal food and drinking water were provided daily. All experimental operations were carried out in accordance with the guidelines for animal care and use of the Animal Research Institute of Zhejiang University.

[0062] 1.2 Construction of mouse light damage model

[0063] Using a light box with a length of 108 cm, a width of 50 cm, and a height of 72 cm, the light intensity was detected by a light intensity meter to be 8500 - 10000 Lux. After eye examination of the mice, mice with normal eyes were randomly divided into a control group (12 mice), a model group (10 mice), a lutein group (100 mg / kg, 10 mice), a deguelin low-dose group (2 mg / kg, 10 mice), and a deguelin high-dose group (4 mg / kg, 10 mice). Lutein and deguelin were suspended in a 5% sodium carboxymethyl cellulose (CMC-Na) solution and administered by gavage once a day. Mice in the blank and model groups were gavaged with an equal volume of 5% CMC-Na. After continuous administration for 10 days, 36 hours after dark treatment of the mice in the model group, the lutein group, the deguelin low-dose group, and the high-dose group, atropine ophthalmic gel was applied to both eyes of the mice to cause bilateral pupil dilation. The mice were placed in a self-made lighting device with a light intensity of 8000 - 10000 Lux (the blank group was raised in a normal environment) and given continuous light for 24 hours. After the light exposure of each group of mice ended, blood was collected by enucleation and the eyeball tissues were collected for relevant tests in subsequent experiments.

[0064] 1.3 Experimental Instruments

[0065] The main instruments used in the experiment included a dehydrator, an embedding machine, a pathological slicer, a tissue spreading machine, an oven, glass slides, an upright optical microscope, an imaging system, a light intensity meter, an LED lamp, an electronic balance, an ultra-low temperature refrigerator, a pure water instrument, a shaker, an enzyme label instrument, etc.

[0066] 1.4 Experimental Consumables and Reagents

[0067] The consumables and reagents required for the experiment included atropine sulfate ophthalmic gel, FAS eyeball fixative, PBS buffer, malondialdehyde (MDA) content detection kit, Mouse IL-6 ELISA kit, xylene, differentiation solution, blueing solution, neutral gum, absolute ethanol, xylene, environmentally friendly dewaxing solution, proteinase K, DAPI dye, anti-fluorescence quenching mounting medium, hematoxylin-eosin (H&E) high-definition constant staining kit, etc.

[0068] 1.5 Histopathological Detection

[0069] For each group, 5 - 6 mice's eyeball tissues were subjected to H&E staining and apoptotic cell TUNEL fluorescence staining, and the histopathological changes of the mice's eyeball tissues were observed using an optical microscope (completed by Wuhan Saiwei'er Biotechnology Co., Ltd.).

[0070] The retina is the most crucial part of the eye, and its hierarchical structure includes the retinal ganglion cell layer, the inner nuclear layer of the retina, the outer nuclear layer of the retina, and the retinal pigment epithelium. The outer nuclear layer of the retina is mainly composed of photoreceptor cells such as rod cells and cone cells, which can receive light stimuli and convert light signals into electrical signals. The inner nuclear layer of the retina contains different types of neuron cells that can convert electrical signals into nerve impulses. It can be seen that the inner / outer nuclear layer cells of the retina play an important role in the reception and conduction of visual signals. The results of retinal H&E staining are as Figure 2 shown, Figure 2 in which, ****P < 0.0001; #P < 0.05; ##P < 0.01; P < 0.001, * indicates the statistical difference between the model group and the normal control group, and # indicates the statistical difference between different drug administration groups and the model group. Light damage caused morphological changes such as loosening and reduced thickness in the outer nuclear layer and inner nuclear layer of the retina in the model group of mice, indicating that light significantly caused damage to retinal cells ( Figure 2 in A). Both low-dose and high-dose administration of deguelin could well improve the morphological changes in the inner / outer nuclear layer of the retina caused by light and increase the thickness of the outer nuclear layer and inner nuclear layer ( Figure 2 in A-C), indicating that deguelin could better improve the cell damage in the retina caused by light.

[0071] The results of TUNEL fluorescence staining of retinal tissue are as Figure 3 shown, Figure 3 in which, ***P < 0.001; ##P < 0.01, #P < 0.05, * indicates the statistical difference between the model group and the control group, # indicates the statistical difference between different drug administration groups and the model group, and ns indicates no significant difference compared with the model group. Light induced a large number of apoptotic cells in the retina of the model group of mice (red fluorescence, Figure 3 in A), while high-dose deguelin (4 mg / kg) could significantly improve the cell apoptosis in the retina caused by light ( Figure 3 in A-B), indicating that deguelin has an improving effect on retinal cell apoptosis caused by light.

[0072] 1.6 Determination of plasma MDA level in mice

[0073] Collect the blood of mice into an anticoagulant tube, centrifuge at 3000 RPM for 10 min at 4 °C, and collect the upper plasma. Determine the content of MDA according to the method provided by the kit manufacturer.

[0074] Plasma malondialdehyde (MDA) is one of the main products of cell membrane lipid peroxidation, and its content can be used as an index of lipid peroxidation to reflect the degree of cell membrane lipid peroxidation. The results of plasma MDA level are as Figure 4 shown, Figure 4**P<0.01; #P<0.05, * indicates statistical difference between model group and control group, # indicates statistical difference between different drug administration groups and model group, ns indicates no significant difference compared with model group. Light exposure caused an increase in plasma MDA level in model group mice, while 4 mg / kg deguelin could significantly reduce the level of MDA, indicating that deguelin can reduce the level of cell membrane lipid peroxidation and has a protective effect on oxidative stress damage caused by light exposure.

[0075] 1.7 Determination of plasma interleukin-6 (IL-6) levels

[0076] The mouse plasma after centrifugation was taken to measure the level of IL-6, the method is as follows:

[0077] (1) Move all reagents to room temperature (18-25°C) and equilibrate for at least 30 minutes. Prepare the reagents according to the method provided by the kit manufacturer and set aside.

[0078] (2) Sample addition: Set up standard wells and test sample wells respectively. Add 100 μL of standard or serum to each well.

[0079] (3) Add detection antibody: Add 50 μL of detection antibody working solution to each well to be tested.

[0080] (4) Incubation: Seal the plate with a sealing film, shake at 200 rpm, and incubate at 28°C for 1.5 h.

[0081] (5) After the incubation, wash, add enzyme, and add substrate for color development according to the method provided by the kit manufacturer. Finally, add 100 μL of stop solution to each well, and the color changes from blue to yellow. Within 30 minutes after the reaction is terminated, use a microplate reader to measure the OD value at the maximum absorption wavelength of 450 nm and the reference wavelength of 630 nm.

[0082] Interleukin is a type of cytokine produced by a variety of cells and acts on a variety of cells. It has an important regulatory role. It plays an important role in transmitting information, activating and regulating immune cells, and mediating inflammatory responses. Figure 5 As shown, Figure 5 **P<0.01; #P<0.05, * indicates the statistical difference between the model group and the normal control group, # indicates the statistical difference between different drug groups and the model group, and ns indicates no significant difference compared with the model group. Light exposure can lead to an increase in the plasma IL-6 level in the model group mice, indicating that light exposure leads to an increase in IL-6-mediated inflammatory response in the body, and both 2mg / kg and 4mg / kg doses of deguelin can significantly reduce the level of IL-6 in the body, indicating that deguelin has an improving effect on the cellular inflammatory response caused by light exposure.

[0083] Although the above embodiments have described the present invention in detail, they are only a part of the embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on this embodiment without creative efforts, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Application of deguelin in the preparation of eye care products.

2. The application according to claim 1, characterized in that The eye care products include at least one of the following functions: (1) treating and / or preventing eye diseases related to retinal light damage; (2) treating and / or alleviating eye symptoms related to retinal light damage; (3) relieving visual fatigue.

3. The application according to claim 2, characterized in that, The eye care products include at least one of the following effects: (a) protecting Müller cells from strong light damage; (b) improving cell damage in the retina caused by light; (c) improving retinal cell apoptosis caused by light; (d) having a protective effect on oxidative stress damage caused by light; (e) improving cell inflammatory response caused by light; (f) relieving visual fatigue.

4. The application according to claim 1, characterized in that, The types of the eye care products include foods, drugs and / or medical device products.

5. Application of deguelin in the preparation of drugs related to the prevention and / or treatment of retinal light damage diseases.

6. A drug related to the prevention and / or treatment of retinal light damage diseases, characterized in that, It includes deguelin and pharmaceutically acceptable excipients.

7. The drug according to claim 6, characterized in that, The working concentration of the deguelin is not less than 30 μM.

8. Application of deguelin in the preparation of functional foods for relieving visual fatigue.

9. A functional food for relieving visual fatigue, characterized in that, Taking deguelin as the active ingredient, it also includes food-acceptable excipients.

10. The functional food according to claim 9, wherein The dosage forms of the functional foods include at least one of the following: ointments, powders, liquids, tablets, gels, capsules and granules.

Images